{
    "clinical_study": {
        "@rank": "46940", 
        "acronym": "ANRSCO23CUPILT", 
        "biospec_descr": {
            "textblock": "Serum and plasma"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy, safety and tolerability of\n      direct-acting antivirals therapy in liver transplanted patients who experienced HCV\n      recurrence.\n\n      This cohort is multicentric with constitution of biobank (plasma, serum) and the prospective\n      collect of biological and clinical data's in the liver transplanted patients with recurrent\n      HCV infection and treated with direct-acting anti-HCV agents."
        }, 
        "brief_title": "Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection", 
        "completion_date": {
            "#text": "September 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HCV Recurrence", 
            "Liver Transplantation", 
            "Direct-acting Antiviral Agents"
        ], 
        "condition_browse": {
            "mesh_term": "Recurrence"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years-old\n\n          -  Liver transplanted patient\n\n          -  Hepatitis C virus infection before transplantation\n\n          -  HCV recurrence with a detectable HCV RNA before enrollment in cohort\n\n          -  Use of at least one direct-acting antiviral agents with or without association with\n             peginterferon and with or without association with ribavirin\n\n          -  Treated by direct-acting antiviral agents or has been yet completed the treatment but\n             still on follow up\n\n          -  Affiliated  to Health Insurance\n\n          -  Written Signed consent form\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding female"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Liver transplant patients with recurrent hepatitis C virus infection treated with\n        direct-acting antiviral agents and followed up in centers of transplantation of the\n        university hospitals."
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01944527", 
            "org_study_id": "2013-A00941-44"
        }, 
        "intervention_browse": {
            "mesh_term": "Antiviral Agents"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 18, 2013", 
        "location": {
            "contact": {
                "email": "Claire.FOUGEROU@chu-rennes.fr", 
                "last_name": "Claire Fougerou, PhD", 
                "phone": "0033299283715"
            }, 
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35033"
                }, 
                "name": "Claire Fougerou"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents", 
        "overall_contact": {
            "email": "Claire.FOUGEROU@chu-rennes.fr", 
            "last_name": "Claire Fougerou, PhD", 
            "phone": "+33 2 99 28 37 53"
        }, 
        "overall_official": {
            "affiliation": "HOSPITAL SAINT ELOI", 
            "last_name": "Georges Philippe Pageaux, Professsor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Sustained virological response (SVR) at 12 weeks after the end of the treatment (SVR defined as undetectable HCV RNA measured by PCR en real time at 12 weeks after antiviral therapy discontinuation)", 
            "measure": "The rate of sustained virological response 12 weeks after discontinuation of direct-acting anti-HCV therapy in liver transplanted patients with HCV recurrence", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after discontinuation of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01944527"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Detectability of HCV RNA according to real time PCR", 
                "measure": "Virological responses at 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during treatment and 4,12,24,48 weeks after treatment discontinuation", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during  treatement and 4,12,24,48 weeks after treatment discontinuation"
            }, 
            {
                "description": "Clinical and laboratory parameters (hepatic, renal, hematological in particular) to assess safety and recording of adverse events", 
                "measure": "Tolerability of direct acting antiviral HCV agents", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during  treatment and 4,12,24,48 weeks after treatment discontinuation"
            }, 
            {
                "description": "Trough blood concentration of immunosuppressive drugs", 
                "measure": "Drug-drug interactions", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during  treatement and 4,12,24,48 weeks after treatment discontinuation"
            }, 
            {
                "measure": "To evaluate emergence of viral resistance to direct-acting antivirals agents", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during  treatement and 4,12,24,48 weeks after treatment discontinuation"
            }, 
            {
                "description": "The rate of anticipated antiviral treatment discontinuation because of intolerability or of severe adverse events", 
                "measure": "To establish predictive factors of treatment failure and of emergence of viral resistance", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during  treatement and 4,12,24,48 weeks after treatment discontinuation"
            }, 
            {
                "description": "The rate of graft loss", 
                "measure": "Evaluate the incidence of graft loss and acute rejection", 
                "safety_issue": "No", 
                "time_frame": "Day 0, 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during  treatement and 4,12,24,48 weeks after treatment discontinuation"
            }, 
            {
                "measure": "Impact on concomitant therapy on virological responses and safety", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 1,2,3,4,6,8,12,16, 20, 24, 36, 48 weeks during  treatment and 4,12,24,48 weeks after treatment discontinuation"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}